The Potential Implications of the Alzheimer’s Drug Donanemab

Alzheimer’s Drug Donanemab Shows Promise in Slowing Disease Progression Introduction A major clinical trial has revealed that the Alzheimer’s drug donanemab, developed by US pharmaceutical giant Eli Lilly, can slow down the rate of cognitive decline in patients. Although it is not a cure, the results offer hope that this therapy could one day halt […]